Back

Study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function (BalanceD-HF): background and design

31 August 2026 (09:50 - 10:00)
Organised by: Logo
Congress Presentation Part of: Multi-organ frailty: liver fibrosis, kidney, and left atrial remodelling Comorbidities ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor John R Teerlink

San Francisco Veterans Affairs Medical Centre, San Francisco (United States of America)

5 More presentations in this session

Presentation thumbnail
Frailty redefines the prognostic value of multimorbidity in heart failure
Doctor V. Copeland (Ramat Gan, IL)
Abstract
Presentation thumbnail
Liver fibrosis in heart failure patients is associated with adverse outcomes, signs of congestion, and ⍺v integrin-related processes: insights from BIOSTAT-CHF
Mr M. Tow (Dundee, GB)
Abstract
Presentation thumbnail
Performance of an artificial intelligence-based smartphone application to assess frailty in older patients with heart failure
Mr S. Tahara (Sapporo, JP)
Abstract
Presentation thumbnail
Metabolomic signature predicting ejection fraction recovery in recent-onset dilated cardiomyopathy
Doctor Y. Xie (CN)
Abstract
Presentation thumbnail
Left atrial remodeling and microstructural damage in the internal capsule in heart failure: a comparison based on left atrial maximum volume index stratification
Doctor C. Pan (Zhuhai, CN)
Abstract

Access the full session

Session thumbnail
Multi-organ frailty: liver fibrosis, kidney, and left atrial remodelling

The Event

Event poster

ESC Congress 2026

31 August 2026 09:50 CET
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF
29 August 2020
thumbnail
Congress Session
Finerenone: a disease-modifying therapy for heart and kidney protection
27 August 2023
thumbnail
Congress Presentation
CardioPROTECTion with dapagliflozin in breast cancer patients treated with AnthrAcycline - PROTECTAA TRIAL: rationale and design.
21 June 2025
thumbnail
Congress Presentation
Early treatment of heart failure: a non-interventional observational study programme of patients with heart failure and initiated on dapagliflozin (EVOLUTION HF)
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources